Compare GameStop Corp. (GME) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Moderna, Inc. — how do they compare? GameStop Corp. trades at $26.56 (market cap $12.75B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 6.2× GameStop Corp.'s market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 13,026,993). Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Moderna, Inc. for 59 Days on average.
| GME | MRNA | |
|---|---|---|
Market Cap | $12.75B | $78.65B |
Volume | 13,026,993 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.56 | $225.00 |
52-Week Low | $17.87 | $22.36 |
Typical Hold Time | 62 Days | 59 Days |
Enterprise Value | $12.03B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $25.28, up 2.85% today, with a bullish technical signal and strong insider buying. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's balance sheet is robust with $4.77 billion in cash and low debt, while profitability improved significantly with a net income margin of 3.43% in 2025.
Outlook remains positive due to strong cash reserves and insider confidence, but risks include revenue decline and competitive pressures. Analyst consensus is cautious with only 16.67% buy ratings. The stock's valuation metrics suggest moderate pricing relative to earnings and sales.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
